Elsevier logo

Publisher: Elsevier

Volume 35, Number 3, September 2001
Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

< previous issue | next issue > | all issues

The Bridge - September 2001
pp. 315-315(1)
Author: Reichen J.

Bone disease in primary biliary cirrhosis: independent indicators and rate of progression
pp. 316-323(8)
Authors: Menon K.V.N.; Angulo P.; Weston S.; Dickson E.R.; Lindor K.D.

Apolipoprotein E polymorphism, a marker of disease severity in primary biliary cirrhosis?
pp. 324-328(5)
Authors: Corpechot C.; Benlian P.; Barbu V.; Chazouilleres O.; Poupon R.E.; Poupon R.

Early shifts of adrenal steroid synthesis before and after relief of short-term cholestasis
pp. 329-337(9)
Authors: Zietz B.; Wengler I.; Messmann H.; Lock G.; Scholmerich J.; Straub R.H.

The prognostic value of histology in the assessment of patients with Budd-Chiari syndrome
pp. 338-343(6)
Authors: Tang T.J.; Batts K.P.; de Groen P.C.; van Hoek B.; Haagsma E.B.; Hop W.C.J.; Janssen H.L.A.

Venesection therapy of insulin resistance-associated hepatic iron overload
pp. 344-349(6)
Authors: Guillygomarc'h A.; Mendler M.H.; Moirand R.; Laine F.; Quentin V.; David V.; Brissot P.; Deugnier Y.

Transglutaminase-mediated cross-linking is involved in the stabilization of extracellular matrix in human liver fibrosis
pp. 367-375(9)
Authors: Grenard P.; Bresson-Hadni S.; El Alaoui S.; Chevallier M.; Vuitton D.A.; Ricard-Blum S.

Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis
pp. 376-385(10)
Authors: Paizis G.; Gilbert R.E.; Cooper M.E.; Murthi P.; Schembri J.M.; Wu L.L.; Rumble J.R.; Kelly D.J.; Tikellis C.; Cox A.; Smallwood R.A.; Angus P.W.

Modulation of collagen XVIII/endostatin expression in lobular and biliary rat liver fibrogenesis
pp. 386-391(6)
Authors: Jia J.-D.; Bauer M.; Sedlaczek N.; Herbst H.; Ruehl M.; Hahn E.G.; Riecken E.O.; Schuppan D.

Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen alpha1(I) and TIMP-1
pp. 392-398(7)
Authors: Jia J.-D.; Bauer M.; Cho J.J.; Ruehl M.; Milani S.; Boigk G.; Riecken E.O.; Schuppan D.

Quantitation of hepatic hepatitis C virus RNA in patients with chronic hepatitis C. Relationship with severity of disease, viral genotype and response to treatment
pp. 399-405(7)
Authors: Gervais A.; Martinot M.; Boyer N.; Auperin A.; Le Breton V.; Degott C.; Valla D.; Marcellin P.

Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial
pp. 406-411(6)
Authors: Barbaro G.; Zechini F.; Pellicelli A.M.; Francavilla R.; Scotto G.; Bacca D.; Bruno M.; Babudieri S.; Annese M.; Matarazzo F.; Di Stefano G.; Barbarini G.; for the Lamivudine Italian Study Group Investigators

Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
pp. 421-430(10)
Authors: Bruix J.; Sherman M.; Llovet J.M.; Beaugrand M.; Lencioni R.; Burroughs A.K.; Christensen E.; Pagliaro L.; Colombo M.; Rodes J.

Abnormal hepatic enhancement on CT in congestive heart failure
pp. 431-431(1)
Authors: de las Heras D.; Pages M.

Steatosis in chronic hepatitis C: can weight reduction improve therapeutic efficacy?
pp. 432-433(2)
Authors: Giannini E.; Ceppa P.; Testa R.

Reply
pp. 433-433(1)
Authors: Clouston A.D.; Hickman I.J.; Macdonald G.A.; Jonsson J.R.; Powell E.E.

< previous issue | next issue > | all issues

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A